Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
Development
|
July 25 2007
Miraculins announces final results of prostate cancer biomarker study Miraculins Inc., a Canadian biotechnology company dealing with the discovery and validation of cancer biomarkers, announces final results from its PCSC04 study.
|
|
July 23 2007
Arius begins toxicology program for lead anti-cancer Arius Research Inc. has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
|
|
July 23 2007
LifeCycle Pharma to initiate Phase II clinical trial of LCP-AtorFen LifeCycle Pharma A/S initiates a Phase II clinical trial program using LCP-AtorFen, a fixed-dose combination of atorvastatin and fenofibrate, for the treatment of high cholesterol levels. LCP-AtorFen will be a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG).
|
|
July 23 2007
Protox announces positive clinical data from prostate cancer study Protox Therapeutics Inc. announces positive top-line results from its Phase I clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer following radiation failure. The trial results indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity following a single intra-prostatic treatment.
|
|
July 13 2007
SemBioSys achieves critical APO AI milestone SemBioSys Genetics Inc. has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AIMilano (collectively referred to as Apo AI) in safflower seed lines. Apo AI is believed by many clinicians to be the basis for the next generation of cardiovascular drugs, which represented a $35 billion market in 2006.
|
|
July 06 2007
AEterna Zentaris presents detailed Phase I results for anti-cancer compound AEterna Zentaris Inc. presented a poster outlining detailed Phase I results for its targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog, AEZS-108 (formerly named AN-152 and ZEN-008), in female patients with cancers expressing LHRH receptors.
|
|
July 06 2007
Four week therapy with Transition Therapeutics' E1-I.N.T.(TM) leads to sustained reduction in blood glucose levels Transition Therapeutics Inc. announces the results from its exploratory Phase IIa clinical trial indicating that four weeks of daily treatments with gastrin-based therapy, E1-I.N.T.(TM), showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for 6 months post-treatment.
|
|
July 06 2007
Capital Health and University of Alberta launch Alberta's first Phase I clinical trials facility Following its recent pledge to increase research investment in Edmonton from $10 million to $75 million per year by 2010, the Northern Alberta Clinical Trials and Research Centre (NACTRC), a joint venture of the University of Alberta and Capital Health, is unveiling a new Phase I clinical trials facility within the Dr. Peter Crockford Clinical Investigation Unit (CIU) at Capital Health's University of Alberta Hospital.
|
|
July 05 2007
CIHR president resigns Dr Alan Bernstein, president of the Canadian Institutes of Health Research (CIHR) and regarded by many as Canada's top scientist has informed Tony Clement, the federal minister of health and CIHR's governing council that he will be resigning his position, effective Oct. 31, 2007.
|
|
June 29 2007
Amorfix presents vCJD blood test results from its commercial high-throughput platform Amorfix Life Sciences announces that Dr. Neil Cashman, chief scientific officer of Amorfix, presented an overview of the company's proprietary Epitope Protection (EP) technology for the in vitro detection of variant Creutzfeldt-Jacob Disease (vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held in Berlin, Germany.
|
|
June 29 2007
Sod turning celebration launches U of S International Vaccine Centre Representatives of all three levels of government and the Canada Foundation for Innovation turned the sod to launch construction of the International Vaccine Centre (InterVac) at the University of Saskatchewan, a $110.4-million project that will significantly enhance Canada's capacity to fight infectious disease in both animals and humans.
|
|
June 25 2007
Osta announces promising pre-clinical results on a new cancer drug Osta Biotechnologies Inc. announces the results of a pilot pre-clinical efficacy study on its lead anti-cancer therapeutic agent OB-24 in a human melanoma xenograft mouse model. Data from this pre-clinical study showed a statistically significant reduction in tumor volumes in groups treated with OB-24, compared to untreated groups and groups treated with dacarbazine.
|
|
June 25 2007
Allon Therapeutics presents at International CNS Disease Congress Allon Therapeutics Inc. was invited to present Allon's clinical progress and strategy for AL-108 at the 3rd Annual CNS Diseases Congress, which took place June 25th to 26th, in Boston. The presentation by Dr. Bruce Morimoto, Allon's VP of Drug Development, was titled 'Neuroprotection by AL-108, an Intranasal Peptide'.
|
|
June 25 2007
Senopsys and Patheon collaborate to develop palatable drug products Senopsys LLC, signs a collaboration agreement with Patheon Inc., a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. Through this collaboration, Senopsys clients will have access to prototype drug formulations manufactured by Patheon and Patheon will be able to offer its clients taste assessment and optimization services.
|
|
June 25 2007
LifeCycle Pharma to initiate Phase II clinical trial of LCP-Tacro for organ transplantation LifeCycle Pharma will initiate a Phase II clinical trial of LCP-Tacro for the prevention of organ rejection in kidney transplant patients following the update of its initial Investigational New Drug Application (IND) in the United States.
|
|
June 11 2007
Isotechnika receives approval to participation in Phase 3 European/Canadian clinical trial Isotechnika Inc. announces that it has received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 in patients suffering from moderate to severe psoriasis.
|
|
June 11 2007
Protox completes prostate cancer trial recruitment Protox Therapeutics Inc. completes recruitment of patients for its Phase I study of PRX302 to treat localized, recurrent prostate cancer. The company is on track to report top line data from this study by mid year.
|
|
June 11 2007
Allon Therapeutics confirms oral bioavailability of AL-309 Allon Therapeutics Inc. releases new data confirming that the company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.
|
|
June 11 2007
Viventia Biotech initiates patient treatment for Vicinium Phase II bladder cancer trial Viventia Biotech Inc. initiates patient treatment in its open-label Phase II clinical trial for Vicinium(TM), administered using intravesical instillation for the treatment of locally persistent non-invasive bladder cancer. The trial, which will initially enroll patients in Canada before expanding into the U.S., is expected to be fully enrolled by Q4 2007.
|
|
May 28 2007
BioMS Medical completes patient recruitment for multiple sclerosis trial BioMS Medical Corp has completed patient recruitment in its phase II clinical trial of MBP8298, for the treatment of relapsing-remitting MS (RRMS). The trial, named MINDSET-01, includes approximately 215 patients, and is being conducted at 24 trial sites in six countries across Europe.
|
|
May 28 2007
Spectrum Pharmaceuticals discloses Phase II data for Ozarelix Spectrum Pharmaceuticals Inc., a partner of Aeterna Zentaris, announces the release of phase II safety and efficacy data for Ozarelix, its prime drug candidate for the treatment of benign prostatic hypertrophy (BPH).
|
|
May 28 2007
Final data published in Phase I/II clinical trial of bladder cancer drug Viventia Biotech Inc., a privately held biopharmaceutical company has secured final data from its dose escalation Phase I/II clinical trial of Vicinium(TM) in patients with high risk, non-invasive bladder cancer.
|
|
May 11 2007
WEX files clinical trial application with Health Canada for Tectin WEX Pharmaceuticals Inc. files a clinical trial application with the Biologics and Genetics Therapies Directorate (BGTD) of Health Canada for Tectin(TM), the lead candidate in the company's Tetrodotoxin (TTX) technology platform.
|
|
May 11 2007
Resverlogix advances RVX-208 IND program to parallel human microdosing Resverlogix Corp. announces favourable results from previously announced toxicology studies, enabling Resverlogix to advance development timing on its RVX-208 Investigational New Drug (IND) program. The official IND enabling studies are now being initiated and the IND is targeted for submission during the third quarter of 2007.
|
|
April 25 2007
Inflazyme receives Helicon's statement regarding preliminary results of IPL455,903 in Phase 2a memory study Inflazyme Pharmaceuticals Ltd. receives a statement from Helicon Therapeutics of New York regarding the outcome of the proof of concept Phase 2a study with IPL455,903 (HT-0712) in Age Associated Memory Impairment (AAMI).
|
|
April 25 2007
BioMS Medical's pivotal multiple sclerosis trial receives positive interim safety analysis BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol.
|
|
April 25 2007
Resverlogix announces milestone ApoA-l/HDL proof of concept data Resverlogix Corp. releases pivotal proof-of-concept data in non-human primates for the NexVas PR program. Interim results from a long term study in adult African Green monkeys demonstrate that oral administration once daily of RVX-208 for 28 days increased the levels of serum ApoA-I and HDL-cholestero
|
|
April 25 2007
Stem Cell Therapeutics Corp. announces positive interim results Stem Cell Therapeutics Corp. announces positive interim results from its currently enrolling Phase IIa- Safety Trial study 'Beta-hCG + Erythropoietin in Acute Stroke'.
|
|
April 18 2007
A triumph over Eczema? According to in-vitro trials run by Allegiance Equity Corp., the anti-inflammatory and antibacterial nature of a key component of the companys drug Relieva, may make the drug useful in treating patients with Atopic Dermatitis, a form of eczema.
|
|
April 13 2007
Urodynamix Expands NIRS intra-abdominal pressure study Urodynamix Technologies Ltd. receives notification from Health Canada allowing the company to expand its clinical trial ('NIRS IAP Study') at the Foothills Medical Centre in Calgary. Under the approved protocol the company may enroll up to 70 intensive care unit ('ICU') patients and will monitor subjects continuously for up to seven days.
|
|
April 13 2007
PainCeptor pharma raises $24.4 M Series B investment round PainCeptor Pharma Corp., a pharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain has raised $24.4 million in a Series B investment round.
|
|
April 13 2007
BioMS Medical's pivotal multiple sclerosis trial receives positive interim safety analysis BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the company's pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol.
|
|
April 12 2007
Proteins as Drugs: Overcoming Hurdles and Future Challenges This year, the Crossroad of Biotechnology will present the 12th edition of its annual conference, to be held at the Biotechnology Research Institute of the National Research Council (NRC-BRI), June 13-14.
|
|
April 12 2007
FDA approves Alexion's Soliris for all patients with PNH Alexion Pharmaceuticals, Inc. receives marketing approval from the U.S. Food and Drug Administration (FDA) for Soliris (eculizumab). Soliris is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction or hemolysis.
|
|
April 02 2007
Isotechnika's independent data monitoring committee conducts review Isotechnika Inc. announces that an independent data monitoring committee (DMC) has met and reviewed the interim data from the Phase 2b kidney transplant (PROMISE) trial.
|
|
April 02 2007
Funding announcement expands Trent University's role as centre for anti-viral development Peterborough, ON, MP Dean Del Mastro announces that the federal government will provide $2 million to support the next development phase of the International Consortium on Anti-Virals (ICAV), headquartered at Trent University.
|
|
March 30 2007
New cardioprotective drug could provide for post-bypass surgery heart health Stent thrombosis, restenosis and lifelong prescriptions. Millions of patients have discovered that the drug-coated stents used as part of their heart operations may be having more of a detrimental effect on their health than medical experts have ever publicly acknowledged.
|
|
March 19 2007
UBC researcher finds new way to treat devastating fungal infections Devastating blood-borne fungal infections that can be lethal for HIV/AIDS, cancer and organ transplant patients may be treated more successfully, thanks to a new drug delivery method developed by researchers at the University of British Columbia in Vancouver.
|
|
March 19 2007
Allon product AL-108 successful in Phase Ib clinical trial Allon Therapeutics Inc. announces that the results of the completed Phase Ib clinical trial of its product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing.
|
|
March 19 2007
Chemokine Therapeutics Corp. announces positive preliminary data Chemokine Therapeutics Corp. announces positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the company's anti-cancer drug candidate.
|
|
March 16 2007
Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 Liponex Inc., a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called 'good cholesterol,' announces results of the Phase I/II Clinical Trial of its lead product, CRD5.
|
|
March 12 2007
Cytochroma Inc. completes $21 million in financing for vitamin D technologies Cytochroma Inc., a spin-off of Queen's University's PARTEQ Innovations, has secured Cdn$21 million in new financing to advance its product development programs targeting vitamin D deficiency and related diseases in chronic kidney disease.
|
|
March 12 2007
Bioanalytical Contract Research A Brief Commentary
Contract research may be described as a service sector within the scientific community that has silently contributed to modern day advancements in drug discovery and development. |
|
March 12 2007
Early Researcher Award Goes to Trent University Professor Trent University biology Professor Marguerite Xenopoulos was elated that she'd be able to further her research into the impact of climate change on freshwater ecosystems when she learned that she won a major Early Researcher Award, valued at $150,000, from the Ministry of Research and Innovation.
|
|
March 12 2007
Canadian Government to Invest in Vaccine Research Development Facility The Canadian government will invest in an ambitious new vaccine research and development facility at the University of Saskatchewan, which will significantly enhance Canada's capacity to develop vaccines for both humans and animals.
|
|
March 09 2007
Pain drug development booming, reports anesthesiologist The number of new drugs being developed to relieve neuropathic pain - a chronic, devastating condition affecting 3-8% of the population - has quadrupled over the past year and a half, a Queen's University study shows.
|
|
March 02 2007
Health Canada approves significant new medical claims for COLD-fX CV Technologies Inc. announces that Health Canada has approved wide-ranging new health claims for COLD-fX. After an extensive review, the Natural Health Products Directorate (NHPD) - Health Canada's division responsible for evaluating the safety, efficacy and quality of natural health products (NHPs) - has issued a product license and natural product number (NPN) for COLD-fX.
|
|
March 02 2007
BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial BioMS Medical Corp announces that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS.
|
|
February 19 2007
First-ever depression in the workplace study unveiled A first ever US-Canada Forum on Mental Health will bring scientists and business executives together from both countries to forge a 'cure and prevention strategy' for major mental illnesses.
|
|
February 19 2007
Zelos Therapeutics Ostabolin-CTM increases bone mineral density in Phase II trial Zelos Therapeutics Inc. announces top-line results from a Phase II study of its novel parathyroid hormone (PTH) analogue, Ostabolin-C, in postmenopausal women with osteoporosis. Ostabolin-C is cyclic PTH (1-31), a proprietary PTH analogue that has demonstrated strong bone building activity in preclinical studies and is in late stage clinical development for the treatment of osteoporosis.
|